Transcode Total Stockholder Equity from 2010 to 2025
| RNAZ Stock | USD 0.52 0.07 11.86% |
Total Stockholder Equity | First Reported 2010-12-31 | Previous Quarter 1.9 M | Current Value 1.8 M | Quarterly Volatility 5.5 M |
Check Transcode Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Transcode Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 55.3 K, Tax Provision of 0.0 or Net Interest Income of 17.9 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.56. Transcode financial statements analysis is a perfect complement when working with Transcode Therapeutics Valuation or Volatility modules.
Transcode | Total Stockholder Equity |
Latest Transcode Therapeutics' Total Stockholder Equity Growth Pattern
Below is the plot of the Total Stockholder Equity of Transcode Therapeutics over the last few years. It is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. Transcode Therapeutics' Total Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Transcode Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Total Stockholder Equity | 10 Years Trend |
|
Total Stockholder Equity |
| Timeline |
Transcode Total Stockholder Equity Regression Statistics
| Arithmetic Mean | 903,707 | |
| Coefficient Of Variation | 604.18 | |
| Mean Deviation | 3,055,855 | |
| Median | (1,109,783) | |
| Standard Deviation | 5,459,981 | |
| Sample Variance | 29.8T | |
| Range | 23.8M | |
| R-Value | 0.37 | |
| Mean Square Error | 27.5T | |
| R-Squared | 0.14 | |
| Significance | 0.15 | |
| Slope | 427,957 | |
| Total Sum of Squares | 447.2T |
Transcode Total Stockholder Equity History
About Transcode Therapeutics Financial Statements
Transcode Therapeutics investors use historical fundamental indicators, such as Transcode Therapeutics' Total Stockholder Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Transcode Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Stockholder Equity | 1.9 M | 1.8 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Transcode Stock Analysis
When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.